Xanomeline 131986-45-3

Xanomeline is a muscarinic acetylcholine receptor agonist with reasonable selectivity for the M₁ and M₄ subtypes. It has been studied for the treatment of both Alzheimer's disease and schizophrenia, particularly the cognitive and negative symptoms, although gastrointestinal side effects led to a high drop-out rate in clinical trials. Despite this, xanomeline has been shown to have reasonable efficacy for the treatment of schizophrenia symptoms, and one recent human study found robust improvements in verbal learning and short-term memory associated with xanomeline treatment.

read more [+]

Systematic (IUPAC) name:	3-(4-hexoxy-1,2,5-thiadiazol-3-yl)-1-methyl-5,6-dihydro-2H-pyridine
Xanomeline CAS number:	131986-45-3
ATC code:
PubChem:	60809
DrugBank:
Formula:	C14H23N3O1
Molecular mass:	281.42 g/mol
Xanomeline Assay/Purity:	Typically NLT 98%

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.